Intravitreal triamcinolone acetonide: a change in a paradigm
1Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, Ruprecht Karls University of Heidelberg, Heidelberg, Germany. Jost.Jonas@augen.ma.uni-heidelberg.de
Ophthalmic Research
|June 10, 2006
Summary
Intravitreal triamcinolone injections effectively treat various intraocular diseases, particularly edematous conditions, improving visual acuity. However, potential side effects like increased intraocular pressure and cataracts necessitate further randomized studies.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Ocular Therapeutics
Background:
- The vitreous cavity is increasingly utilized for direct drug delivery to treat intraocular diseases.
- Intravitreal drug administration builds upon experimental and clinical work by Machemer, Peyman, and others.
Purpose of the Study:
- To review the efficacy and safety of intravitreal triamcinolone acetonide for various intraocular conditions.
- To compare treatment responses and side effects across different ocular diseases.
Main Methods:
- Review of experimental studies and clinical observations.
- Analysis of outcomes and complications associated with intravitreal triamcinolone acetonide injections.
Main Results:
- Triamcinolone acetonide shows best visual acuity gains in intraretinal edematous diseases (e.g., diabetic macular edema, vein occlusions).
- Effective in noninfectious uveitis, potentially as an angiostatic agent, and for ocular hypotony.
- Complications include ocular hypertension (40%), cataract formation (15-20%), and endophthalmitis (1:1,000).
- Duration of effect is 6-9 months (20 mg) or 2-4 months (4 mg) in nonvitrectomized eyes.
Conclusions:
- Intravitreal triamcinolone injection is a promising treatment for several intraocular diseases.
- Considered an experimental procedure pending results from randomized controlled trials.
- Potential for combination therapy with antiangiogenic or neuroprotective agents in the future.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...